ArticleNeurology2013
Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI.
Article in Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- A paradigm of the diagnosis and treatment for the whole process of Alzheimer's disease.Annals of medicine · 2026Review
- Differential atrophy along the longitudinal axis of the hippocampus in Alzheimer's disease and suspected non-Alzheimer's disease pathophysiology (SNAP).Neuroradiology · 2026Article
- Association of soluble tumor necrosis factor receptor 1 with tau pathology, brain atrophy, and cognitive decline: a longitudinal study.BMC medicine · 2026Article
- Estimation of reference curves for brain atrophy and analysis of robustness to machine effects.Scientific reports · 2025Article
- Association of peripheral immunity with cognition, neuroimaging, and Alzheimer's pathology.Alzheimer's research & therapy · 2022Article
- Validation of the Alzheimer's disease-resemblance atrophy index in classifying and predicting progression in Alzheimer's disease.Frontiers in aging neuroscience · 2022Article
- Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer's Disease Neuroimaging Initiative.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Article
- Increased Brain Glucose Uptake After 12 Weeks of Aerobic High-Intensity Interval Training in Young and Older Adults.The Journal of clinical endocrinology and metabolism · 2018Article
- Profiling heterogeneity of Alzheimer's disease using white-matter impairment factors.NeuroImage. Clinical · 2018Article
- Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies.Journal of Alzheimer's disease : JAD · 2018Article
- Feasibility and acceptance of simultaneous amyloid PET/MRI.European journal of nuclear medicine and molecular imaging · 2016Article
- Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.JAMA neurology · 2016Article
- Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.European archives of psychiatry and clinical neuroscience · 2016Article
- The New Criteria for Alzheimer's Disease - Implications for Geriatricians.Canadian geriatrics journal : CGJ · 2016Article
- [Not Available].Canadian geriatrics journal : CGJ · 2016Article
- Suspected non-Alzheimer disease pathophysiology--concept and controversy.Nature reviews. Neurology · 2016Review
- Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015Review
- Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveWe describe the operationalization of the National Institute on Aging-Alzheimer's Association (NIA-AA) workgroup diagnostic guidelines pertaining to Alzheimer disease (AD) dementia in a large multicenter group of subjects with AD dementia.
methodsSubjects with AD dementia from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with at least 1 amyloid biomarker (n = 211) were included in this report. Biomarker data from CSF Aβ42, amyloid PET, fluorodeoxyglucose-PET, and MRI were examined. The biomarker results were assessed on a per-patient basis and the subject categorization as defined in the NIA-AA workgroup guidelines was determined.
resultsWhen using a requirement that subjects have a positive amyloid biomarker and single neuronal injury marker having an AD pattern, 87% (48% for both neuronal injury biomarkers) of the subjects could be categorized as "high probability" for AD. Amyloid status of the combined Pittsburgh compound B-PET and CSF results showed an amyloid-negative rate of 10% in the AD group. In the ADNI AD group, 5 of 92 subjects fit the category "dementia unlikely due to AD" when at least one neuronal injury marker was negative.
conclusionsA large proportion of subjects with AD dementia in ADNI may be categorized more definitively as high-probability AD using the proposed biomarker scheme in the NIA-AA criteria. A minority of subjects may be excluded from the diagnosis of AD by using biomarkers in clinically categorized AD subjects. In a well-defined AD dementia population, significant biomarker inconsistency can be seen on a per-patient basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.